News

FDA Commissioner, Scott Gottlieb, MD, announced the FDA’s efforts to advance the development of gene therapies through the addition of 6 scientific guidance documents.

Abbott’s updated MitraClip is a catheter-bases system that provides an alternative to open heart surgery for repairing mitral regurgitation.

A few months after performing a first-of-its-kind procedure in the US, members of the John Ochsner Heart and Vascular Institute surgical team explore what led to the surgical success.

The Cleveland Clinic’s pioneer of minority programs plans to end health disparity.

Analysis of data from the Danish Birth Registry showed that tonsillectomies were associated with nearly triple relative risk of disease of the respiratory tract.

The FDA’s approval of Brineura in April 2017 was a landmark moment for patients with the CLN2 form of the disease, but those with the other 13 forms of Batten are still waiting.

The HVAD system is the only approved LVAD approved for implant via thoracotomy or median sternotomy.

Friedreich’s ataxia treatment, omaveloxolone, received orphan drug designation from the European Commission.

Only 3.03% of the SPI group reported suicidal behaviors, compared to 5.29% of those receiving usual care during the 6-month follow-up period.

To the knowledge of researchers, this is the first demonstration to show C3a can stimulate basal deposit production by normal human RPE cells.

Researchers suggest a need exists for integration of hepatitis C treatment into all facets of addiction care for individuals who inject drugs.

Converting from brand-name levetiracetam to generic version does not greatly increase seizure frequency among patients with epilepsy.

Currently, FDA-approved fluoroquinolones include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin, gemifloxacin (Factive) and delafloxacin (Baxdela).

An isotopic-reinforced polyunsaturated fatty acids shows a reduction in cognitive deficits in a preclinical in vivo model of Huntington disease.

The issuance was in response to a request by the DoD, and after the FDA received a declaration from the Secretary of the Department of Health and Human Services.

Several promising new treatment developments are offering a ray of hope to Huntington’s patients, their at-risk children, and the clinicians who treat them.

The Center for Inquiry has filed a lawsuit against CVS for consumer fraud due to its sale and marketing of homeopathic medicines.

An online prevention program that uses a soap opera format was shown to be effective at lowering rates of STIs.

Similar to the phase 2 MoveDMD trial, the phase 3 POLARIS trial will share the same patient population and functional endpoints.

Researchers measured the VMAT2 inhibitors for clinical effectiveness, cost-effectiveness, and budget impact of these medications.

First-line protease inhibitors posed different risks for cardiovascular disease in an international study of adverse events in HIV patients.

At 48 months, intervention patients significantly fewer incidence rates for CIN3+ versus control patients, with a risk ratio of 0.42.

Data from the Alcyone MEMS Cannula (AMC), which can intratumorally administer the oncolytic adenovirus, may be an effective diffuse intrinsic pontine glioma (DIPG) treatment, according to recently presented data.

An analysis of pediatric ICU interactions found that physicians are far more likely to get a beneficial response from families when they show empathy to their emotions.

Previously, the benefit of exercise in mediating both CVD and depression was documented, but the association between midlife fitness with later depression and death from heart disease had not been.

Skyhawk Therapeutics and Celgene Corporation have entered into a 5-year partnership to discover, develop, and commercialize small molecule treatment options for patients with neurological diseases.

A modelling study showed that injectable PrEP could be more effective at reducing HIV transmission than oral PrEP.

CLR 131 was granted an orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of Ewing’s sarcoma, a rare pediatric cancer.

The FDA agreed to remove a boxed warning from inhalant combinations of corticosteroid and long-acting beta-agonist following research from a collaboration of pharmaceutical manufacturers.

Utilizing research from the Age-Related Eye Disease Study 2, researchers found that MA and GA may be part of the same disease process affecting the visual acuity of patients with AMD.